R&D Innovation R&D Innovation
    R&D Innovation
    R&D Pipeline
    Therapeutic Areas
    Drug Name
    Modality
    Target
    Indications
    Pre-clinical
    Phase I
    Phase II
    Phase III
    NDA Submitted
    Launch
    Therapeutic Areas Drug Name Modality Target Indications Pre-clinical Phase I Phase II Phase III NDA Submitted Launch
    Infectious Diseases Dongwei’en (Emitasvir Phosphate) NCE NS5A Hepatitis C
    Dong’antai (Netanasvir Phosphate)* NCE NS5A Hepatitis C
    Dong’anqiang (Encofosbuvir)* NCE NS5B Hepatitis C
    Dong’andi (Morphothiadine Mesylate) NCE HBV
    capsid    		 Hepatitis B
    Dong’anrui (Freethiadine) NCE HBV
    capsid    		 Hepatitis B
    HECN30227 NCE HBV RNA Hepatitis B
    HEC191834 NCE TLR8 Hepatitis B
    Chronic Diseases Dongjiantang (Olorigliflozin) NCE SGLT-2 Diabetes
    Guangjianyou (Insulin glargine (U.S.)) biosesimilar IR Diabetes
    HEC88473 NCE GLP-1/
    FGF21    		 Diabetes, Obesity, NASH
    Dongjiandi (Yinfenidone Hydrochloride) NCE - IPF
    HEC53856 NCE HIF-
    PHD    		 Renal anemia
    Dongtongshen (Mitizodone Phosphate) NCE 5-HT, 5-HT1a, 5-HT1b Depression
    HEC95468 NCE SGC PAH
    HEC93077 NCE XO/
    URAT1    		 Gout
    HEC96719 NCE FXR NASH
    HEC169584 NCE THR-β NASH
    HEC137076 NCE 5-HT1f Migraine
    Amlodipine Besylate Granules Improved new drug CCB Hypertension, Coronary heart disease
    HECB1502201 Improved new drug P-CABs Peptic ulcer bleeding
    HECB1701301 Improved new drug NMDA AD
    Oncology Dongningchun (Clifutinib Besylate) NCE FLT3 AML
    Dongningguan (Larotinib Mesylate) NCE EGFR ESCC
    HEC53856 NCE HIF-
    PHD    		 CIA
    HEC169096 NCE RET Tumors
    HEC201625 NCE PD-L1 Tumors
    Overseas Clinical Programs Filed/Initiated
    Licensing/Transfer/Co-Development
    Research Project Sponsorship

    The company undertakes R&D for over twenty national "Major New Drug Innovation" projects and supports dozens of research initiatives for national and local governments.

    Patent Applications
    2400 +
    Total Patent Applications Filed
    350
    PCT Applications
    1200 +
    Total Granted Patents Worldwide
    • The innovative drug project Emitasvir Phosphate was awarded the First Prize in the 2023 China (Xiaoshan) Biopharmaceutical High-Value Patent Cultivation Competition
      The innovative drug project Emitasvir Phosphate was awarded the First Prize in the 2023 China (Xiaoshan) Biopharmaceutical High-Value Patent Cultivation Competition
    • Silver Award in the 2020 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Patent Cultivation and Layout Competition
      Silver Award in the 2020 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Patent Cultivation and Layout Competition
    • First recognized as National Intellectual Property Model Enterprise in 2017
      First recognized as National Intellectual Property Model Enterprise in 2017
    站点地图